- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05298111
Acute Effect of MMT Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes
March 15, 2024 updated by: Ong Ying Qian, Universiti Sultan Zainal Abidin
Acute Effect of Melon Manis Terengganu Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes
Open-label, randomised, placebo-controlled, crossover study with two intervention arms.
The study was conducted in 30 respondents and the primary objective is to show an improved glycemic response after Melon Manis Terengganu (MMT) peel powder consumption in people at risk of type 2 diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The main aim of the study is to investigate the acute effect of MMT peel powder on glycemic response in people at risk of type 2 diabetes.
Besides, the acute effect of MMT peel powder on perceived satiety and energy intake were explored.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Terengganu
-
Kuala Terengganu, Terengganu, Malaysia, 21300
- Food Preparation and Therapeutic Diet Lab, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Gong Badak Campus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 59 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Modified Finnish Type 2 Diabetes Risk Assessment Tool (FINDRISC) score ≥ 4
- Capillary fasting blood glucose (FBG) < 7.0 mmol/L
- Malaysian
- Live, work or study in Kuala Nerus, Terengganu
- Both gender
- Age 18 to 59 years old
- Non-smoker
- Those taking supplement agree to undergo washout period of one week
Exclusion Criteria:
- Had clinical history of type 2 diabetes mellitus (T2DM)
- Capillary FBG ≥ 7.0 mmol/L
- Take oral antidiabetic agents
- Participate in other weight management programme or interventional research
- On a prescribed medical diet
- GI illnesses or conditions
- Allergy or sensitivity to study products
- Pregnant, currently breastfeeding, or planning to become pregnant
- On dietary restrictions
- Smoker
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Formulation 3
Formulated MMT peel powder (provide 5 g dietary fiber per day)
|
Respondents were consumed 36 g of Formulation 3 containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
Other Names:
|
|
Placebo Comparator: Control
Glucose
|
Respondents were consumed 4.5 g of control containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Glucose Levels
Time Frame: Baseline (0 min), 30, 60, 90 and 120 minutes on Day 1 and Day 4 of both study visits
|
Blood glucose were measured using glucometer (Accu Chek Performa, New South Wales, Australia) from finger-prick blood samples according to the standard operating procedure at baseline (0 min), 30, 60, 90 and 120 minutes.
|
Baseline (0 min), 30, 60, 90 and 120 minutes on Day 1 and Day 4 of both study visits
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perceived Satiety (Area Under the Curve)
Time Frame: Day 1 and 4 of both study visits
|
Perceived satiety measurements were rated using a 10-cm visual analogue scale (VAS) which consisted of hunger (How hungry are you?), fullness (How full are you?), desire to eat (How strong is your desire to eat?), prospective food consumption (How much would you be able to eat right now?) and thirstiness (How thirsty are you?) (Tey, Salleh, Henry, & Forde, 2017).
The scale ranged from 0 (not at all) to 10 (very much) measured at baseline (0 min), 30, 60, 90 and 120 minutes.
The area under the curve was calculated using trapezoid rule.
|
Day 1 and 4 of both study visits
|
|
Food Intake
Time Frame: Day 1 and 4 of both study visits
|
The respondents were asked to record all the food or drink they had consumed including sauces, soup and gravies using household measures once they woke up in the morning until they went to sleep at night.
|
Day 1 and 4 of both study visits
|
|
Calories Intake
Time Frame: Day 1 and day 4 of both study visits
|
The respondents were asked to record all the food or drink they had consumed including sauces, soup and gravies using household measures once they woke up in the morning until they went to sleep at night.
|
Day 1 and day 4 of both study visits
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Weight (kg)
Time Frame: Day 1 and 4 of both study visits
|
Body weight was taken at every study visit.
|
Day 1 and 4 of both study visits
|
|
Height (cm)
Time Frame: Day 1 and 4 of both study visits
|
Height was taken at every study visit.
|
Day 1 and 4 of both study visits
|
|
Body Mass Index (BMI) (kg/m^2)
Time Frame: Day 1 and 4 of both study visits
|
BMI was calculated using formula = body weight (kg)/height (m)^2
|
Day 1 and 4 of both study visits
|
|
% Body Fat
Time Frame: Day 1 and 4 of both study visits
|
% body fat was taken at every study visit.
|
Day 1 and 4 of both study visits
|
|
Waist Circumference (cm)
Time Frame: Day 1 and 4 of both study visits
|
Waist circumference was taken at every study visit.
|
Day 1 and 4 of both study visits
|
|
Blood Pressure
Time Frame: Day 1 and 4 of both study visits
|
Blood pressure was measured using an Omron automatic digital blood pressure monitor (Omron HEM-7221) in a seated position at all visits after 5 min of sitting.
|
Day 1 and 4 of both study visits
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Prof Dr Sakinah Harith, Universiti Sultan Zainal Abidin
- Principal Investigator: Dr Norshazila Shahidan, Universiti Sultan Zainal Abidin
- Principal Investigator: Prof Madya Dr Mohd Razif Shahril, National University of Malaysia
- Principal Investigator: Prof Madya Dr Hermizi Hapidin, Universiti Sains Malaysia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ong YQ, Harith S, Shahril MR, Shahidan N, Hapidin H. Acute effect of Melon Manis Terengganu peel powder on glycemic response, perceived satiety, and food intake: a randomized, placebo-controlled crossover trial in adults at risk of type 2 diabetes. BMC Nutr. 2022 Aug 8;8(1):75. doi: 10.1186/s40795-022-00572-1.
- Teh CH, Lim KK, Chan YY, Lim KH, Azahadi O, Hamizatul Akmar AH, Ummi Nadiah Y, Syafinaz MS, Kee CC, Yeo PS, Fadhli Y. The prevalence of physical activity and its associated factors among Malaysian adults: findings from the National Health and Morbidity Survey 2011. Public Health. 2014 May;128(5):416-23. doi: 10.1016/j.puhe.2013.10.008. Epub 2014 Apr 13.
- Tey SL, Salleh NB, Henry J, Forde CG. Effects of aspartame-, monk fruit-, stevia- and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake. Int J Obes (Lond). 2017 Mar;41(3):450-457. doi: 10.1038/ijo.2016.225. Epub 2016 Dec 13.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2021
Primary Completion (Actual)
November 3, 2021
Study Completion (Actual)
November 3, 2021
Study Registration Dates
First Submitted
March 1, 2022
First Submitted That Met QC Criteria
March 16, 2022
First Posted (Actual)
March 28, 2022
Study Record Updates
Last Update Posted (Actual)
August 15, 2024
Last Update Submitted That Met QC Criteria
March 15, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RCTOYQ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on At Risk of Type 2 Diabetes Mellitus
-
University of JenaCompletedDecreased Cardovascular Risk | Decreased Risk of Diabetes Mellitus Type IIGermany
-
Rhode Island HospitalCompletedType 2 Diabetes | At-risk DrinkingUnited States
-
University of Nevada, Las VegasUniversity of Nevada, RenoActive, not recruitingPre Diabetes | At Risk for Type 2 Diabetes MellitusUnited States
-
GlaxoSmithKlineCompletedType 2 Diabetes Mellitus | CV Risk
-
Ohio State UniversityActive, not recruitingType 1 Diabetes | Type 2 Diabetes | Pregnancy, High RiskUnited States
-
King Faisal Specialist Hospital and Research Centre...Not yet recruitingCardiovascular Diseases | Cardiovascular Diseases Risk | Mortality of Patients with CVD | Mortality of Patients with CVD and T2DM | Mortality of Patients with T2DM | Mortality of Patients with Neither | Morbidity of CVD
-
Hospital Carlos III, MadridGerencia de Atención Primaria, MadridCompletedType 2 Diabetes Mellitus | Cardiovascular Risk FactorsSpain
-
University of Massachusetts, WorcesterRecruitingPregnancy, High Risk | Type 2 Diabetes Treated With InsulinUnited States
-
University of AkureyriWestern Norway University of Applied SciencesCompletedCardiovascular Risk Factor | Primary Health Care | Pre-diabetes | T2DM (Type 2 Diabetes Mellitus)Iceland
-
Medical University of ViennaUnknownType 2 Diabetes Mellitus | Endothelial Dysfunction | Cardiovascular RiskAustria
Clinical Trials on Formulation 3
-
PfizerCompleted
-
BayerCompleted
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
Boehringer IngelheimCompleted
-
MedImmune LLCCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaQuotient SciencesRecruitingHealthy ParticipantsUnited Kingdom
-
PfizerCompletedHealthy ParticipantsUnited States
-
University of RoehamptonActive, not recruitingHealthy SubjectsUnited Kingdom
-
GlaxoSmithKlineCompletedHerpes SimplexUnited States, Belgium, Canada, Germany, Spain, United Kingdom, Australia, Estonia